Prefer Biocon over Aurobindo Pharma: Rajat Bose

Rajat Bose of rajatkbose.com told CNBC-TV18, "Aurobindo Pharma is in a range bound situation. I would personally suggest to get into a pharmaceutical stock that is trending and in this case, Biocon would be a case in point. So, my suggestion would be a switch from Aurobindo to Biocon.""Today is the result day and so one should watch for the result. But the problem is that after the results, generally if the results are not up to expectation or below expectation then there would be some selling. So, my point is one should switch to a stronger stock, trending stock and that is Biocon and Biocon's long-term potential is far better than Aurobindo," he added.